Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Next Previous
Search
Trial Profile

A Phase 1, Open-Label Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIIB 080 (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Biogen

Most Recent Events

  • 17 Mar 2025 Status changed from not yet recruiting to recruiting.
  • 10 Jan 2025 Planned End Date changed from 28 Jul 2025 to 30 Jul 2026.
  • 10 Jan 2025 Planned primary completion date changed from 20 Feb 2025 to 16 Feb 2026.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top